Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.3K

Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B

Hyunwoo Oh1, Dae Won Jun2, I-Heng Lee3

  • 1Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea.

Alimentary Pharmacology & Therapeutics
|June 17, 2020
PubMed

Insights

Chronic hepatitis B patients have significantly more liver and non-liver comorbidities than the general population. These comorbidities, including CKD and osteoporosis, increased over time in CHB patients.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Epidemiology

Background:

  • The prevalence of non-liver comorbidities in chronic hepatitis B (CHB) patients remains a subject of debate.
  • Understanding the comorbidity profile of CHB patients is crucial for comprehensive patient care.

Purpose of the Study:

  • To characterize the demographics, comorbidities, and healthcare utilization of CHB patients in South Korea.
  • To compare the comorbidity burden of CHB patients against matched non-CHB controls.

Main Methods:

  • Utilized the Health Insurance Review & Assessment Service (HIRA) database from 2007-2016.
  • Included adult patients with CHB claims, matched with non-CHB controls in a 1:4 ratio using propensity score matching.

Main Results:

  • CHB patients exhibited higher proportions of comorbidities like dyslipidemia, hypertension, chronic kidney disease (CKD), and osteoporosis/fracture (OF) compared to controls.
  • Over 50% of CHB patients had multiple comorbidities (CKD, diabetes, dyslipidemia, OF).
  • CHB patients had significantly higher odds of developing CKD (1.42 times) and OF (1.09 times).

Conclusions:

  • Patients with chronic hepatitis B have a higher prevalence of both liver and non-liver comorbidities.
  • The burden of these comorbidities in CHB patients has increased over the study period.
Abstract

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.8K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

344

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
122
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
116
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
213
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
734
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
448